We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults

By HospiMedica International staff writers
Posted on 27 Oct 2020
Print article
Image: AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults (Photo courtesy of AstraZeneca)
Image: AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults (Photo courtesy of AstraZeneca)
Early trial results of AstraZeneca Plc’s (Cambridgeshire, England) COVID-19 vaccine candidate suggest that the group most vulnerable to serious illness and death could build immunity as the vaccine has been found to trigger protective antibodies and T-cells in older age groups.

AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to a report by The Financial Times, the AstraZeneca-Oxford COVID-19 experimental vaccine triggered protective antibodies and T-cells in older age groups, providing much encouragement to researchers who have been searching for proof of the vaccine’s ability to protect these groups from serious illness or death from the SARS-Cov-2 virus.

Age is now considered as the primary risk factor for COVID-19 severity as the immune system weakens with age. This has raised concerns that a COVID-19 vaccine may fail to protect the very group that generates the least effective response to the SARS-Cov-2 virus. However, early results from immunogenicity blood tests performed on a subset of older participants from trials of the AstraZeneca-Oxford COVID-19 experimental vaccine have shown that the vaccine also triggered protective antibodies and T-cells in older age groups. These results match data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55 years, according to The Financial Times. The earlier data had shown that the vaccine induced both antibodies as well as T-cells for at least 56 days.

Researchers are encouraged by the latest development, although positive immunogenicity tests do not guarantee that a COVID-19 vaccine is safe and effective for older people which can be confirmed only after full trial data for the age group has been analyzed.

Related Links:
AstraZeneca
University of Oxford


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Digital Radiography Generator
meX+20BT lite

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.